Background: The treatment of chronic venous disease, has largely shifted from high ligation and stripping to endovenous thermal ablation (EVTA) techniques, because of its comparable efficacy and lack of invasiveness. This clinical trial aimed to compare the efficacy of two thermal ablation techniques, endovenous laser ablation (EVLA) 1470-nm with Tulip-Tip fiber and radiofrequency ablation (RFA) ClosureFastTM using a non-inferiority design for occlusion rate (primary outcome).

Methods: A prospective multicenter randomized clinical trial randomized 280 patients for the treatment of great saphenous vein (GSV) reflux. Primary outcome was the GSV occlusion rate, secondary outcome factors were the possible side-effects of the treatment such as pain, ecchymosis, quality of Life (CIVIQ-20), revised Venous Clinical Severity Score (r-VCSS). One-year follow-up period.

Results: The total occlusion rates at one year follow-up were 96.4% and 94.5% in the EVLA and RFA groups respectively (P=0.15). Regarding secondary outcomes, such as postoperative CIVIQ-20, r-VCSS, analgesia, absenteeism, there was no significant difference between both treatment groups.

Conclusions: RFA and EVLA, using a 1470 nm laser with Tulip-Tip fiber, of the GSV results in equal occlusion rates at one year, with comparable postoperative pain and improved quality of life.

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-9590.22.04747-2DOI Listing

Publication Analysis

Top Keywords

clinical trial
12
prospective multicenter
8
multicenter randomized
8
randomized clinical
8
endovenous laser
8
laser ablation
8
thermal ablation
8
tulip-tip fiber
8
occlusion rate
8
quality life
8

Similar Publications

Background: Opioids are still being prescribed to manage acute postsurgical pain. Unnecessary opioid prescriptions can lead to addiction and death, as unused tablets are easily diverted.

Methods: To determine whether combination nonopioid analgesics are at least as good as opioid analgesics, a multisite, double-blind, randomized, stratified, noninferiority comparative effectiveness trial was conducted, which examined patient-centered outcomes after impacted mandibular third-molar extraction surgery.

View Article and Find Full Text PDF

Comparative Analysis of Gelatin/Polylactic Acid and Commercial PLA Membranes for Guided Bone Regeneration: A Randomized Clinical Trial.

Med Sci Monit

January 2025

Department of Oral Implantology, The Affiliated Stomatology Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Province Key Laboratory of Oral Biomedicine, Jiangxi Province Clinical Research Center for Oral Disease, Nanchang, Jiangxi, China.

BACKGROUND This study included 32 patients with single missing teeth and alveolar bone defects and aimed to compare outcomes from guided bone regeneration with a gelatin/polylactic acid (GT/PLA) barrier membrane and a Guidor® bioresorbable matrix barrier dental membrane. MATERIAL AND METHODS A total of 32 participants were recruited in the clinical study, with single missing teeth and alveolar bone defects, requiring guided bone regeneration (32 missing teeth in total). They were randomly divided into the GT/PLA membrane group (experimental) and Guidor® membrane group (control) by the envelope method (n=16).

View Article and Find Full Text PDF

Introduction: Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-term safety of LOR within an observational extension of two phase 2 trials.

Methods: This 60-month, observational extension study (NCT02951026) of a 12-month phase 2a trial (NCT02536833) and 6-month phase 2b trial (NCT03122860) was administratively closed after 36 months as data inferences became limited.

View Article and Find Full Text PDF

Background: Early neurological deterioration (END) is associated with a poor prognosis in acute ischemic stroke (AIS). Effectively lowering low-density lipoprotein cholesterol (LDL-C) can improve the stability of atherosclerotic plaque and reduce post-stroke inflammation, which may be an effective means to lower the incidence of END. The objective of this study was to determine the preventive effects of evolocumab on END in patients with non-cardiogenic AIS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!